LED Medical Diagnostics Announces Preliminary Q3 2016 Financial Results

Vancouver, British Columbia - October 20, 2016 - LED Medical Diagnostics Inc. ("LED Medical" or the "Company") is pleased to announce today that preliminary gross revenue numbers for the quarter ending September  30, 2016 are $2.5 million, as measured in US$, representing an approximate 39% increase over the prior year period of $1.8 million. The Company's revenue for the nine-month period ended September 30, 2016 was $8.3 million, a year-over-year increase of 11% as compared to the $7.5 million result from the same period of 2015. These revenue results are preliminary only and subject to finalization by the Company.

"We move into this year’s period of high sales seasonality with two exciting new products to complement our imaging product portfolio," stated Lamar Roberts, President of LED Dental. "The TUXEDO intraoral sensor and the RAYSCAN Alpha Plus extraoral imaging system are expected to make positive contributions to company growth going forward."

For more information, please visit www.leddental.com.

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

The Company is currently listed on the TSX Venture Exchange (TSX-V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.

LED Medical Diagnostics

Investor Relations:

Bristol Capital
Glen Akselrod
Phone: 905.326.1888, ext. 10
Email: glen@bristolir.com

Media Contact:

LED Dental
Chris Koch
Phone: 678.293.9413
Email: chris.koch@leddental.com

Corporate Contact:

LED Medical
David Gane, CEO
Phone: 604-434-4614 x227
Email: david.gane@leddental.com

Forward Looking Statement

This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2015. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.